Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cellular Biomedicine Approved to Start China Stem Cell Trial

publication date: Jan 17, 2019

Cellular Biomedicine, a Shanghai immunotherapy/stem cell company, reported that its off-the-shelf therapy for Knee Osteoarthritis (KOA) was approved to start a China Phase II trial. AlloJoin® is an allogeneic adipose-derived mesenchymal progenitor cell (haMPC) product. It is the first allogeneic stem cell drug application approved for a KOA Phase II clinical trial in China. In December 2017, the China NMPA declared that all cell therapies must comply with the drug IND/NDA process. The AlloJoin IND was approved after a 60-day priority review. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.